<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2448-8909</journal-id>
<journal-title><![CDATA[Medicina crítica (Colegio Mexicano de Medicina Crítica)]]></journal-title>
<abbrev-journal-title><![CDATA[Med. crít. (Col. Mex. Med. Crít.)]]></abbrev-journal-title>
<issn>2448-8909</issn>
<publisher>
<publisher-name><![CDATA[Colegio Mexicano de Medicina Crítica A.C.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2448-89092017000200101</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Paro cardiaco repentino atribuido a miocardiopatía hipertrófica por uso de esteroides anabólicos. Reporte de caso]]></article-title>
<article-title xml:lang="en"><![CDATA[Sudden cardiac arrest attributed to hypertrophic cardiomyopathy by use of anabolic steroids. Case report]]></article-title>
<article-title xml:lang="pt"><![CDATA[Parada cardíaca súbita atribuída a cardiomiopatia hipertrófica pelo uso de esteróides anabolizantes. Informe de um caso]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Díaz Conde]]></surname>
<given-names><![CDATA[Marcelo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Brito Miranda]]></surname>
<given-names><![CDATA[Daniel]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Márquez Villegas]]></surname>
<given-names><![CDATA[Félix Gibrant]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Hernández Pliego]]></surname>
<given-names><![CDATA[Rogelio Ramsés]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Laboratorio AstraZeneca México  ]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
<country>México</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>04</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>04</month>
<year>2017</year>
</pub-date>
<volume>31</volume>
<numero>2</numero>
<fpage>101</fpage>
<lpage>105</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S2448-89092017000200101&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S2448-89092017000200101&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S2448-89092017000200101&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen: La miocardiopatía hipertrófica se caracteriza por hipertrofia asimétrica y no dilatada del ventrículo izquierdo, la muerte súbita es probablemente consecuencia de alteraciones eléctricas impredecibles del miocardio que producen arritmias letales. Las miocardiopatías se definen por la existencia de anomalías estructurales y funcionales del ventrículo izquierdo que no pueden explicarse por enfermedad coronaria o por condiciones de carga anómalas, lo que causa un aumento del grosor de la pared del ventrículo izquierdo. En este grupo de enfermedades existen causas genéticas y no genéticas, dentro de éstas se describen las asociadas al uso de fármacos incluidos los esteroides anabólicos androgénicos. Los esteroides anabólicos androgénicos se utilizan para promover el incremento de masa muscular para mejorar el desempeño de los atletas, esto ha llevado al uso y abuso de estos productos en atletas profesionales y recreacionales. El uso crónico en dosis suprafisiológicas en esta población se asocia a diversas manifestaciones cardiovasculares como miocardiopatía hipertrófica, esta asociación entre el uso de esteroides anabólicos androgénicos y la hipertrofia cardiaca quedó demostrada en un estudio por hallazgos patológicos en usuarios de esteroides anabólicos androgénicos fallecidos.1 El objetivo de esta comunicación es reportar un caso clínico inusual en nuestro ámbito hospitalario de un paciente con uso crónico de esteroides anabólicos androgénicos y miocardiopatía hipertrófica.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract: Hypertrophic cardiomyopathy is characterized by asymmetric and non-dilated left ventricle hypertrophy, sudden death is probably a consequence of unpredictable myocardial electrical disturbances that produce lethal arrhythmias. Cardiomyopathies are defined by the existence of structural and functional abnormalities of the left ventricle that can not be explained by coronary disease or abnormal load conditions causing the increased thickness of the wall of the left ventricle, within this diseases group exists genetic and nongenetic causes, these are described associated drugs including the use of anabolic androgenic steroids. Anabolic androgenic steroids are used to promote increased muscle mass, to improve the performance of athletes, this has led to the use and abuse of these products in professional and recreational athletes, chronic use in supraphysiological dose in this population is attaches a several cardiovascular manifestations as hypertrophic cardiomyopathy, this association between the use of anabolic androgenic steroids and cardiac hypertrophy has been shown in a study by pathological findings in ASS users deceased.1 The purpose of this communication is to report an unusual case in our hospital of a patient with chronic use of anabolic androgenic steroids and hypertrophic cardiomyopathy.]]></p></abstract>
<abstract abstract-type="short" xml:lang="pt"><p><![CDATA[Resumo: A cardiomiopatia hipertrófica é caracterizada por hipertrofia assimétrica e não-dilatada do ventrículo esquerdo, a morte súbita é provavelmente devido a alterações elétricas imprevisíveis do miocárdio que produzem arritmias letais. As cardiomiopatias são definidas pela existência de anomalias estruturais e funcionais do ventrículo esquerdo que não pode ser explicado por doenças coronárias ou condições de cargas anormais que provocam um aumento na espessura da parede ventricular esquerda, dentro deste grupo de doenças existem causas genéticas e não genéticas, dentro destas se descrevem as que estão associadas com o uso de medicamentos, incluindo os esteróides anabólico-androgênicos. Os esteróides anabólico-androgênicos são usados para promover o aumento da massa muscular para melhorar o desempenho dos atletas, o que levou ao uso e abuso desses produtos em atletas profissionais e amadores, o uso crônico em doses suprafisiológicas nesta população está associado a vários eventos cardiovasculares, tais como cardiomiopatia hipertrófica, esta associação entre o uso de esteróides anabólico-androgênicos e hipertrofia cardíaca foi demonstrado em um estudo por um descubrimento patológico em usuários de esteróides anabólico-andrôgenicos falecidos.1 O objetivo do presente informe é relatar um caso clínico incomum em nosso hospital de um paciente com o uso crônico de esteróides anabólico-androgênicos e cardiomiopatia hipertrófica.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Miocardiopatía hipertrófica]]></kwd>
<kwd lng="es"><![CDATA[esteroides anabólicos androgénicos]]></kwd>
<kwd lng="es"><![CDATA[muerte súbita]]></kwd>
<kwd lng="es"><![CDATA[testosterona]]></kwd>
<kwd lng="en"><![CDATA[Hypertrophic cardiomyopathy]]></kwd>
<kwd lng="en"><![CDATA[anabolic androgenic steroids]]></kwd>
<kwd lng="en"><![CDATA[sudden death]]></kwd>
<kwd lng="en"><![CDATA[testosterone]]></kwd>
<kwd lng="pt"><![CDATA[Cardiomiopatia hipertrófica]]></kwd>
<kwd lng="pt"><![CDATA[esteróides anabólico-androgênicos]]></kwd>
<kwd lng="pt"><![CDATA[morte súbita]]></kwd>
<kwd lng="pt"><![CDATA[testosterona]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Far]]></surname>
<given-names><![CDATA[HR]]></given-names>
</name>
<name>
<surname><![CDATA[Ågren]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Thiblin]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cardiac hypertrophy in deceased users of anabolic androgenic steroids an investigation of autopsy findings]]></article-title>
<source><![CDATA[Cardiovasc Pathol]]></source>
<year>2012</year>
<volume>21</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>312-6</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Maisch]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Noutsias]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Ruppert]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Richter]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Pankuweit]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cardiomyopathies classification, diagnosis, and treatment]]></article-title>
<source><![CDATA[Heart Fail Clin]]></source>
<year>2012</year>
<volume>8</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>53-78</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Maron]]></surname>
<given-names><![CDATA[BJ]]></given-names>
</name>
<name>
<surname><![CDATA[Gohman]]></surname>
<given-names><![CDATA[TE]]></given-names>
</name>
<name>
<surname><![CDATA[Aeppli]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prevalence of sudden cardiac death during competitive sports activities in Minnesota high school athletes]]></article-title>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>1998</year>
<volume>32</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>1881-4</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Montisci]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[El Mazloum]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Cecchetto]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Terranova]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Ferrara]]></surname>
<given-names><![CDATA[SD]]></given-names>
</name>
<name>
<surname><![CDATA[Thiene]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Anabolic androgenic steroids abuse and cardiac death in athletes morphological and toxicological findings in four fatal cases]]></article-title>
<source><![CDATA[Forensic Sci Int]]></source>
<year>2012</year>
<volume>217</volume>
<numero>1-3</numero>
<issue>1-3</issue>
<page-range>e13-8</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lusetti]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Licata]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Silingardi]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Reggiani-Bonetti]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Palmiere]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pathological changes in anabolic androgenic steroid users]]></article-title>
<source><![CDATA[J Forensic Leg Med]]></source>
<year>2015</year>
<volume>33</volume>
<page-range>101-4</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Evans]]></surname>
<given-names><![CDATA[NA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Current concepts in anabolic-androgenic steroids]]></article-title>
<source><![CDATA[Am J Sports Med]]></source>
<year>2004</year>
<volume>32</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>534-42</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[van Amsterdam]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Opperhuizen]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Hartgens]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Adverse health effects of anabolic-androgenic steroids]]></article-title>
<source><![CDATA[Regul Toxicol Pharmacol]]></source>
<year>2010</year>
<volume>57</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>117-23</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lichtenfeld]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Deal]]></surname>
<given-names><![CDATA[BJ]]></given-names>
</name>
<name>
<surname><![CDATA[Crawford]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Sudden cardiac arrest following ventricular fibrillation attributed to anabolic steroid use in an adolescent]]></article-title>
<source><![CDATA[Cardiol Young]]></source>
<year>2016</year>
<volume>26</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>996-8</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Basaria]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Coviello]]></surname>
<given-names><![CDATA[AD]]></given-names>
</name>
<name>
<surname><![CDATA[Travison]]></surname>
<given-names><![CDATA[TG]]></given-names>
</name>
<name>
<surname><![CDATA[Storer]]></surname>
<given-names><![CDATA[TW]]></given-names>
</name>
<name>
<surname><![CDATA[Farwell]]></surname>
<given-names><![CDATA[WR]]></given-names>
</name>
<name>
<surname><![CDATA[Jette]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Adverse events associated with testosterone administration]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2010</year>
<volume>363</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>109-22</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Barrientos-Pérez]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Uso de anabólicos por atletas adolecentes]]></article-title>
<source><![CDATA[Rev Endocrinol Nutr]]></source>
<year>2001</year>
<volume>9</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>133-40</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Aguila]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Mercado]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Palma]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Esteroides androgénicos anabolizantes consecuencias en el hombre]]></article-title>
<source><![CDATA[Revista Chilena de Urología]]></source>
<year>2013</year>
<volume>78</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>13-7</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Suárez-Mier]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Anabolizantes Complicaciones cardiovasculares. Muerte súbita e inesperada]]></article-title>
<source><![CDATA[Cuad Med Forense]]></source>
<year>2001</year>
<volume>26</volume>
<page-range>29-39</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fanton]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Belhani]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Vaillant]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Tabib]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Gomez]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Descotes]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Heart lesions associated with anabolic steroid abuse comparison of post-mortem findings in athletes and norethandrolone-induced lesions in rabbits]]></article-title>
<source><![CDATA[Exp Toxicol Pathol]]></source>
<year>2009</year>
<volume>61</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>317-23</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Maron]]></surname>
<given-names><![CDATA[BJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Sudden death in young athletes]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2003</year>
<volume>349</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>1064-75</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Elliott]]></surname>
<given-names><![CDATA[PM]]></given-names>
</name>
<name>
<surname><![CDATA[Anastasakis]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Borger]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Borggrefe]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Cecchi]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Charron]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Guía de práctica clínica de la ESC 2014 sobre el diagnóstico y manejo de la miocardiopatía hipertrófica]]></article-title>
<source><![CDATA[Rev Esp Cardiol]]></source>
<year>2015</year>
<volume>68</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>63.e1-e52</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[D'Andrea]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Limongelli]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Morello]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Mattera-Iacono]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Russo]]></surname>
<given-names><![CDATA[MG]]></given-names>
</name>
<name>
<surname><![CDATA[Bossone]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Anabolic-androgenic steroids and athlete's heart: When big is not beautiful....!]]></article-title>
<source><![CDATA[Int J Cardiol]]></source>
<year>2016</year>
<volume>203</volume>
<page-range>486-8</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bagatell]]></surname>
<given-names><![CDATA[CJ]]></given-names>
</name>
<name>
<surname><![CDATA[Bremner]]></surname>
<given-names><![CDATA[WJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Androgens in men--uses and abuses]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>1996</year>
<volume>334</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>707-14</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
